Lee Eppstein
Technik-/Wissenschafts-/F&E-Leiter bei New Brunswick Scientific Co., Inc.
Profil
Lee Eppstein has worked as a Director at Antyra, Inc. and as a Vice President-Technology at New Brunswick Scientific Co., Inc.
Aktive Positionen von Lee Eppstein
Unternehmen | Position | Beginn |
---|---|---|
New Brunswick Scientific Co., Inc.
New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2000 |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
New Brunswick Scientific Co., Inc.
New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |